China SFDA Okays Commercial Production Of Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's State FDA gave its approval to Sinovac Biotech to begin producing its avian influenza vaccine for humans. The Beijing-based company's general manager said the firm is able to produce new H5N1 vaccines as the virus mutates in humans. The SFDA intends for the vaccine to be on hand in time for the Olympics in Beijing this summer. The agency used a first-time procedure that allows it to approve commercial production at the same time it approves a drug license. Initial supplies of the vaccine are to be held in reserve by the government in case of a major bird flu outbreak. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.